Covetrus, Inc.

$ 20.99 0.00 %

Covetrus, Inc. functions as a technology and services provider for the animal health sector. The company supplies a comprehensive range of animal health consumables, including its own branded and proprietary items, along with diverse equipment (small and large), laboratory supplies, and associated repair services. It further offers a full spectrum of pharmaceuticals—encompassing branded, generic, and vaccine products, surgical instruments, diagnostic kits, infection control solutions, parasiticides, and nutritional supplements—to both wholesale and retail clients. Beyond physical goods, Covetrus delivers critical value-added services such as inventory management, e-commerce platforms, and professional development programs for veterinary practitioners. Its technology portfolio includes practice management software, data analytics applications, and client communication tools aimed at boosting operational efficiency and enhancing business health. These integrated offerings extend to client reminders, data backup, hardware sales and support, and credit card processing capabilities for veterinary practices and clinics. Additionally, the company manages the distribution of finished pharmaceutical products and offers specialty compounding services, complemented by logistics, manufacturer incentives, and data integration support. Covetrus supports veterinary practices and animal health clinics across the companion animal, equine, and livestock sectors, primarily within North America, Europe, and the Asia Pacific. Established in 2018 under the name HS Spinco, Inc. and headquartered in Portland, Maine, Covetrus, Inc. transitioned to private ownership on October 13, 2022.

CEO: Benjamin Wolin - https://www.covetrus.com

Price objectif

-

Recommandation

Hold

DCF

$ -

Loading data...

CVET vs S&P500

Loading data...

No data available.

Quick ratio

1.10

suggests a healthy liquidity position, showing that the company can likely meet its short-term obligations.

P/E ratio

-69.97

may indicate that the company is undervalued or has poor growth prospects.

EPS

-0.30

is the net profit of a company divided by the number of outstanding shares, indicating the profit earned per share.

ROE

-5.64 %

indicates low profitability, suggesting that the company is not using equity efficiently to generate profits.

ROIC

-0.80 %

does not generate enough return to cover its financing costs, which indicates value destruction and may pose long-term profitability issues.

WACC

-

is a company's average cost of capital, weighted by the proportion of debt and equity in its financing. It represents the minimum return the company must generate to satisfy its investors.

Debt-to-Equity Ratio

0.69

indicates that the company uses more equity than debt, suggesting prudent management.

Free cash flow per share

0.31

is a measure of a company's financial flexibility that is determined by dividing free cash flow by the total number of shares outstanding.

Dividend payout ratio

0.00 %

the dividend payout ratio is the measure of dividends paid out to shareholders relative to the company's net income.

Earnings per share

Loading data...

No data available.

Financials

Piotroski score
N/A
Altman score
N/A
Loading data...

No data available.

Cash / Debt

Cash Ratio
0.26 indicates liquidity risk, as the company may not have enough cash to meet its immediate obligations
Debt Ratio
0.31 indicates that the company uses little debt to finance its assets, suggesting good financial stability
Loading data...

No data available.

Free Cash Flow

Loading data...

No data available.

Earnings Per Share (annual)

Loading data...

No data available.

Sales

Loading data...

No data available.